R-IDARAM plus intrathecal chemotherapy

Phase 3Small molecule

R-IDARAM plus intrathecal chemotherapy is one of 11 small molecule programs targeting Immunochemotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunochemotherapyRecruiting

ImmunochemotherapyPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in Immunochemotherapy

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

1 2

Immunotherapy

Bristol-Myers Squibb

Phase 3

3 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 4

Tuoyi

SSun Yat-sen University

Phase 2

1 5

PD-1 Inhibitor

Johnson & Johnson

Phase 2

1 6

Paclitaxel-Albumin

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 2

1 7

Pd-1inhibitor

SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

2 8

Platinum Doublet

Regeneron

Phase 2

1 9

R-IDARAM plus intrathecal chemotherapy

NNavy General Hospital, Beijing

Phase 3

2 10

Adebrelimab Combined With DOS

TTang-Du Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2/3Recruiting

Immunochemotherapy

NCT02657785

Phase 2/3Recruiting

Immunochemotherapy

NCT02836158

Clinical

Trials by Indication[1]

Immunochemotherapy2 trials

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Recruiting·NNavy General Hospital, Beijing·Phase 2/3·NCT02657785·100 enrolled

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

Recruiting·NNavy General Hospital, Beijing·Phase 2/3·NCT02836158·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for R-IDARAM plus intrathecal chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-IDARAM plus intrathecal chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-IDARAM plus intrathecal chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Navy General Hospital, Beijing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNavy General Hospital, Beijing

R-IDARAM plus intrathecal chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Immunochemotherapy2 trials

References

Drug Info

Quick Facts

Related News